Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2024 ·
Decision snapshot: OPK stock price vs CYBR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CYBR's multiple
Needs CYBR P/S.
Implied fair value · at OPK's multiple
Needs Revenue / share.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OPK FY 2025 (ended Dec 31, 2025) · CYBR FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 63% equity / 37% debt · EV / Revenue 2.49x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
OPKO Health, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
CYBERARK SOFTWARE LTD. · implied price per share
The ordinary-share to listed-security ratio could not be verified.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.54x
0.31x
Net debt / EBITDA
Leverage against operating earnings
-3.03x
5.82x
Cash and equivalents
Liquid reserves on the balance sheet
$364.41M
$562.82M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMARIN CORP PLC\UK
OPK vs AMRN
Sarepta Therapeutics, Inc.
OPK vs SRPT
Amphastar Pharmaceuticals, Inc.
OPK vs AMPH
SUPERNUS PHARMACEUTICALS, INC.
OPK vs SUPN
Harmony Biosciences Holdings, Inc.
OPK vs HRMY
Okta, Inc.
OPK vs OKTA
Tenable Holdings, Inc.
OPK vs TENB
CrowdStrike Holdings, Inc.
OPK vs CRWD
Zscaler, Inc.
OPK vs ZS
$687.93M
$729.77M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
